首页> 外文OA文献 >A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD

【2h】

A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD

机译：一次每日氟酸甲酸呋喃/维替者100/25μg与一次每日Vilantolol25μg的随机，期III试验，以评估氟酮源于COPD患者组合中氟酮源性的肺功能的贡献

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Thomas M. Siler; Atsushi Nagai; Catherine A. Scott-Wilson; Dawn A. Midwinter; Courtney Crim;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 mu g versus once-daily vilanterol 25 mu g to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD [J] . Siler Thomas M., Nagai Atsushi, Scott-Wilson Catherine A., Respiratory medicine . 2017,第期

机译：一次每日氟酸甲酸呋喃/维替醇100/25μg的随机，期III试验与一次每日Vilantolol25μg评估氟酮源于COPD患者组合的氟酮源性肺功能的贡献
2. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients [J] . DransfieldM.T., FeldmanG., KorenblatP., Respiratory medicine . 2014,第8期

机译：每日一次糠酸氟替卡松/维兰特罗（100/25 mcg）与每日两次丙酸氟替卡松/沙美特罗（250/50 mcg）的疗效和安全性
3. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD – mixed treatment comparisons of clinical efficacy [J] . Gillian Stynes, Henrik Svedsater, Jaro Wex, Respiratory Research . 2015,第1期

机译：每日一次糠酸氟替卡松/维兰特罗100/25 mcg与每日两次联合治疗COPD –临床疗效的混合治疗比较
4. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD – mixed treatment comparisons of clinical efficacy [O] . Gillian Stynes, Henrik Svedsater, Jaro Wex, 2015

机译：每日一次糠酸氟替卡松/维兰特罗100/25 mcg与每日两次联合治疗COPD –临床疗效的混合治疗比较
5. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients [O] . Dransfield Mark T., Feldman Gregory, Korenblat Phillip, 2014

机译：每天一次糠酸氟替卡松/维兰特罗（100 / 25mcg）与每日两次丙酸氟替卡松/沙美特罗（250 / 50mcg）的疗效和安全性

A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD

著录项

引文网络

相似文献

相关主题

期刊订阅